VistaGen Therapeutics Inc Market Cap ($8.18 Million)
Market Cap & Net Worth: VistaGen Therapeutics Inc (VTGN)
VistaGen Therapeutics Inc market cap. VistaGen Therapeutics Inc (NASDAQ:VTGN) has a market capitalization of $8.18 Million ($8.18 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27432 globally and #5692 in its home market, demonstrating a 5.92% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying VistaGen Therapeutics Inc's stock price $0.18 by its total outstanding shares 44376911 (44.38 Million). Also see VistaGen Therapeutics Inc cash flow conversion for how efficiently the company converts equity into cash flow.
VistaGen Therapeutics Inc Market Cap History (2015–2026)
VistaGen Therapeutics Inc market cap history from 2015 to 2026. Data shows change from $13.10 Billion to $8.18 Million (-47.74% CAGR). Check VTGN stock price and chart for real-time trading data and today's change.
Index Memberships
VistaGen Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #776 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #2515 of 3165 |
Weight: VistaGen Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
VistaGen Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how VistaGen Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore VTGN net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
6.44x
VistaGen Therapeutics Inc's market cap is 6.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.48 Billion | $1.25 Million | -$10.26 Million | 1185.82x | N/A |
| 2020 | $2.58 Billion | $334.00K | -$20.77 Million | 7732.74x | N/A |
| 2021 | $2.60 Billion | $1.09 Million | -$17.93 Million | 2382.79x | N/A |
| 2022 | $137.12 Million | $1.11 Million | -$47.76 Million | 123.66x | N/A |
| 2023 | $228.10 Million | $-227.30K | -$59.25 Million | -1003.51x | N/A |
| 2024 | $130.91 Million | $1.06 Million | -$29.36 Million | 123.04x | N/A |
| 2025 | $29.37 Million | $486.00K | -$51.42 Million | 60.44x | N/A |
| 2026 | $8.18 Million | $1.27 Million | -$69.69 Million | 6.44x | N/A |
Competitor Companies of VTGN by Market Capitalization
Companies near VistaGen Therapeutics Inc in the global market cap rankings as of November 5, 2026. Also see VTGN current and non-current assets for a full breakdown of the balance sheet.
Key companies related to VistaGen Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of VistaGen Therapeutics Inc (2015–2026)
Market capitalization of VistaGen Therapeutics Inc from 2015 to today. Between 2015 and today, VistaGen Therapeutics Inc's market cap moved from $13.10 Billion to $ 8.18 Million, with a yearly change of -47.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.18 Million | -72.16% |
| 2025 | $29.37 Million | -77.56% |
| 2024 | $130.91 Million | -42.61% |
| 2023 | $228.10 Million | +66.34% |
| 2022 | $137.12 Million | -94.72% |
| 2021 | $2.60 Billion | +0.52% |
| 2020 | $2.58 Billion | +181.28% |
| 2019 | $918.20 Million | -54.02% |
| 2018 | $2.00 Billion | +34.72% |
| 2017 | $1.48 Billion | -70.15% |
| 2016 | $4.97 Billion | -62.09% |
| 2015 | $13.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of VistaGen Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.18 Million USD |
| MoneyControl | $8.18 Million USD |
| MarketWatch | $8.18 Million USD |
| marketcap.company | $8.18 Million USD |
| Reuters | $8.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About VistaGen Therapeutics Inc
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an od… Read more